These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 2660266)
1. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Fischetti VA; Hodges WM; Hruby DE Science; 1989 Jun; 244(4911):1487-90. PubMed ID: 2660266 [TBL] [Abstract][Full Text] [Related]
2. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. Bessen D; Fischetti VA J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296 [TBL] [Abstract][Full Text] [Related]
3. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Bessen D; Fischetti VA Infect Immun; 1988 Oct; 56(10):2666-72. PubMed ID: 2458320 [TBL] [Abstract][Full Text] [Related]
4. Expression of streptococcal M protein in mammalian cells. Hruby DE; Hodges WM; Wilson EM; Franke CA; Fischetti VA Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5714-7. PubMed ID: 3041416 [TBL] [Abstract][Full Text] [Related]
5. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus. Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396 [TBL] [Abstract][Full Text] [Related]
7. Intranasal immunisation of mice with a streptococcal peptide-based vaccine. Relf W; Hayman W; Russell-Jones G; Good M Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788 [No Abstract] [Full Text] [Related]
8. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. Dale JB; Chiang EC J Infect Dis; 1995 Apr; 171(4):1038-41. PubMed ID: 7706785 [TBL] [Abstract][Full Text] [Related]
10. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Mannam P; Jones KF; Geller BL Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651 [TBL] [Abstract][Full Text] [Related]
11. A novel vaccine against Streptococcus equi ssp. zooepidemicus infections: the recombinant swinepox virus expressing M-like protein. Lin HX; Huang DY; Wang Y; Lu CP; Fan HJ Vaccine; 2011 Sep; 29(40):7027-34. PubMed ID: 21807055 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines. Bronze MS; McKinsey DS; Beachey EH; Dale JB Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732 [No Abstract] [Full Text] [Related]
13. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. Bronze MS; Courtney HS; Dale JB J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521 [TBL] [Abstract][Full Text] [Related]
14. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions. Fischetti VA; Bessen DE; Schneewind O; Hruby DE Adv Exp Med Biol; 1991; 303():159-67. PubMed ID: 1805563 [No Abstract] [Full Text] [Related]
15. Assembly and analysis of a functional vaccinia virus "amplicon" containing the C-repeat region from the M protein of Streptococcus pyogenes. Hruby DE; Schneewind O; Wilson EM; Fischetti VA Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3190-4. PubMed ID: 2014239 [TBL] [Abstract][Full Text] [Related]
16. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155 [TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci. Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813 [TBL] [Abstract][Full Text] [Related]
18. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. Dale JB; Baird RW; Courtney HS; Hasty DL; Bronze MS J Infect Dis; 1994 Feb; 169(2):319-23. PubMed ID: 8106764 [TBL] [Abstract][Full Text] [Related]
19. Group A streptococcal antigens and vaccine potential. Kehoe MA Vaccine; 1991 Nov; 9(11):797-806. PubMed ID: 1722063 [TBL] [Abstract][Full Text] [Related]
20. Structure-based design of broadly protective group a streptococcal M protein-based vaccines. Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]